CPRX250117P15000
- 0.00
- 0.000.00%
Catalyst Pharmaceuticals Newsroom
Catalyst Pharmaceuticals Price Target Maintained With a $30.00/Share by B of A Securities
Catalyst Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating With 58.7% Upside Potential
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Stephens Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $35
Catalyst Pharmaceuticals Analyst Ratings
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $36
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Catalyst Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $30
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27
Catalyst Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
Catalyst Pharmaceuticals Analyst Ratings